Form 4: Arcellx CMO Sells Shares Under 10b5-1 Plan
Insider Transaction Report
Arcellx Chief Medical Officer Christopher Heery sold 340 shares of common stock for $90 per share on November 17, 2025, under a pre-arranged 10b5-1 trading plan.
Summary
- Christopher Heery, Chief Medical Officer of Arcellx, Inc., reported a sale of common stock.
- The transaction involved the disposition of 340 shares of Arcellx, Inc. common stock.
- The shares were sold at a price of $90 per share.
- The sale occurred on November 17, 2025.
- This transaction was executed pursuant to a Rule 10b5-1 trading plan, which was established by Mr. Heery on March 23, 2025.
- Following this transaction, Mr. Heery beneficially owns 284 shares of Arcellx, Inc. common stock.
Sentiment
Score: 5
Explanation: A routine insider transaction disclosure under a pre-arranged trading plan, which is generally considered neutral as it's often for personal financial planning rather than a signal about company performance.
Positives
- NA
Negatives
- NA
Risks
- NA
Future Outlook
NA
Management Comments
- NA
Industry Context
This is a routine insider transaction disclosure and does not provide information directly related to broader industry trends or competitive landscape.
Comparison to Industry Standards
- NA
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| NA | NA | NA | NA | NA |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| NA | NA | NA | NA |
Legal Proceedings
- NA
Related Party Transactions
- NA
Stakeholder Impact
- Shareholders: Disclosure of insider selling activity, which can sometimes be interpreted negatively, though mitigated by the pre-arranged 10b5-1 plan, suggesting the sale is for personal financial planning rather than a reaction to new company-specific information.
Next Steps
- NA
Key Dates
| Date | Description |
|---|---|
| 03/23/2025 | Date Rule 10b5-1 trading plan was entered into by the Reporting Person. |
| 11/17/2025 | Date of the reported transaction (sale of common stock). |
Recommendation
holdThe sale of shares by the Chief Medical Officer was conducted under a pre-arranged 10b5-1 trading plan, indicating it was not based on new material non-public information. Such routine sales for personal financial planning purposes typically do not warrant a change in investment recommendation unless the volume is exceptionally large or the timing is unusual relative to company news. This transaction alone does not provide sufficient new information to alter a 'hold' stance on Arcellx stock.
Keywords
Arcellx, ACLX, Form 4, Insider Trading, Stock Sale, Christopher Heery, Chief Medical Officer, 10b5-1 Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.